Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sage Therapeutic Com
(NQ:
SAGE
)
8.000
+0.090 (+1.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,269,307
Open
7.900
Bid (Size)
7.500 (2)
Ask (Size)
8.160 (3)
Prev. Close
7.910
Today's Range
7.730 - 8.130
52wk Range
7.700 - 28.26
Shares Outstanding
59,762,106
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Starbucks, Sage, Outset Medical, and Super Micro and Encourages Investors to Contact the Firm
September 04, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
SAGE Class Action Alert: Robbins LLP Reminds Stockholders of the Sage Therapeutics, Inc. Class Action
September 04, 2024
From
Robbins LLP
Via
GlobeNewswire
Performance
YTD
-64.41%
-64.41%
1 Month
-10.71%
-10.71%
3 Month
-27.07%
-27.07%
6 Month
-62.14%
-62.14%
1 Year
-61.11%
-61.11%
More News
Read More
SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
September 03, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Expert Outlook: Sage Therapeutics Through The Eyes Of 14 Analysts
July 30, 2024
Via
Benzinga
Analyst Expectations For Sage Therapeutics's Future
July 12, 2024
Via
Benzinga
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
September 03, 2024
From
Schall Law
Via
GlobeNewswire
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Sage Therapeutics, Inc. Investors of Upcoming Deadline
September 03, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
REMINDER – Sage Therapeutics, Inc. Investor Alert: Robbins LLP Reminds Shareholders of the SAGE Class Action Lawsuit
September 02, 2024
From
Robbins LLP
Via
Business Wire
SAGE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sage Therapeutics, Inc. and Encourages Investors to Contact the Firm
August 30, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Rosen Law Firm Urges Sage Therapeutics, Inc. (NASDAQ: SAGE) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
August 30, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
SAGE INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
August 30, 2024
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) INVESTOR ALERT: Investors With Large Losses in Sage Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
August 30, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Stockholder Notice: Robbins LLP Informs Stockholders of the Class Action Filed Against Sage Therapeutics, Inc.
August 29, 2024
From
Robbins LLP
Via
GlobeNewswire
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 29, 2024
From
The Schall Law Firm
Via
Business Wire
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
August 04, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
July 31, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Sage Therapeutics, Inc. (SAGE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
July 26, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 24, 2024
Via
Benzinga
Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints
July 24, 2024
Via
Benzinga
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
July 24, 2024
Via
Investor's Business Daily
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
July 24, 2024
Via
InvestorPlace
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
July 24, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Netflix To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Friday
July 19, 2024
Via
Benzinga
Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
July 17, 2024
From
Sage Therapeutics, Inc.
Via
Business Wire
Delta Air Lines Posts Downbeat Earnings, Joins United Airlines, American Airlines And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
July 11, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.